Table E4.
Pediatric patients with asthma reviewed by the participating centers, in the past and during the COVID-19 pandemic
| Patients reviewed | Overall cohort | COVID-19 burden (deaths/million) |
Clinical setting |
||||
|---|---|---|---|---|---|---|---|
| <10 | 10-100 | >100 | Primary | Secondary | Tertiary | ||
| No. of consultations per respondent per week, median (IQR) | 20 (10-25) | 12.5 (5-20) | 18 (14-28) | 20 (10-25) | 20 (10-25) | 5 (5-10) | 20 (11-24) |
| No. of participants contributing data, N | 61 | 22 | 10 | 23 | 13 | 9 | 34 |
| Total no. of patients evaluated weekly by respondents, N | 1,727 | 326 | 301 | 785 | 292 | 69 | 1081 |
| Annualized estimate of patients evaluated, N | 89,804 | 16,952 | 15,652 | 40,820 | 15,184 | 3,588 | 56,212 |
| No. of patients evaluated per respondent during the preceding month, median (IQR) | 35 (20-60) | 25 (10-40) | 38 (21-60) | 48 (20-68) | 50 (10-100) | 25 (10-30) | 40 (20-60) |
| No. of participants contributing data, N | 59 | 22 | 14 | 22 | 13 | 9 | 37 |
| Total no. of patients evaluated during the preceding month by participants, N | 3,593 | 820 | 728 | 1,925 | 870 | 214 | 2,509 |
| Annualized estimate of patients evaluated, N | 43,116 | 9,840 | 8,736 | 23,100 | 10,440 | 2,568 | 30,108 |
| No. of new patients per respondent per week, during COVID-19, median (IQR) | 5 (3-9) | 3.5 (2-5) | 4 (3-6) | 5 (3-10) | 5 (2-8) | 4 (4-5) | 5 (3-10) |
| No. of participants contributing data, N | 27 | 10 | 4 | 9 | 8 | 2 | 14 |
| Total no., N | 194 | 63 | 20 | 74 | 62 | 8 | 97 |
| No. of patients receiving biologics in the clinic, median (IQR) | 11 (5-20) | 5 (3-10) | 9 (5-15) | 20 (10-30) | 10 (5-17) | 3 (3-3) | 11 (6-20) |
| No. of participants contributing data, N | 38 | 8 | 9 | 20 | 4 | 1 | 32 |